Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616632 | 0.84 | CA2 (0.35) | CA2CA1CA4CA7CA12 | |
| SCHEMBL4778303 | 0.78 | CYP2A6 (0.32) | CYP2A6CA2CA1CA4CA7 | |
| SCHEMBL335048 | 0.75 | CA2 (0.38) | CA2CA1 | |
| SCHEMBL3880729 | 0.71 | LMNA (0.38) | CA2CA1CA4CA7CA12 | |
| SCHEMBL6152123 | 0.68 | CA2 (0.35) | CA2CA1CA4CA7CA12 | |
| SCHEMBL1796470 | 0.67 | CA1 (0.33) | CA2CA1CA4CA7CA12 | |
| SCHEMBL4000892 | 0.64 | CA12 (0.38) | CA2CA1CA12CA9 | |
| SCHEMBL1797009 | 0.63 | — | — | |
| SCHEMBL336386 | 0.63 | — | — | |
| SCHEMBL1523787 | 0.62 | CA2 (0.46) | CA2CA1CA12CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170536-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008011337-A1 | HCV INHIBITORS | ABBOTT LABORATORIES (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011337-A1 | HCV INHIBITORS | ABBOTT LABORATORIES (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | NQO2, RSU1, RRS1 | CYP2A6 342/4885CA2 3689/4885CA1 4775/4885 |
| US-20100120753-A1 | Anti-Infective Agents | RSU1, NQO2, RRS1 | CYP2A6 390/4885CA2 3663/4885CA1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.